Cangrelor use in a 6-year-old patient undergoing complex percutaneous coronary intervention after post-surgical myocardial infarction. (16th November 2020)

• Record Type: Journal Article
• Authors: Sirico, Domenico; Morici, Nuccia; Soriano, Francesco; Marianeschi, Stefano Maria; Pedrazzini, Giovanna; Leonardi, Sergio; Vignati, Gabriele
• Is Part Of: Platelets. Volume 31:Number 8(2020)
• Page Start: 1090
• Page End: 1093
• Publication Date: 2020-11-16
• Subjects: Cangrelor -- congenital heart disease -- coronary compression -- myocardial infarction -- PCI; Blood platelets -- Periodicals; Blood Platelets -- Periodicals; 615.39
• DOI: 10.1080/09537104.2020.1732323
• Languages: English
• ISSNs: 0953-7104

Abstract

Abstract: Cangrelor is an intravenously administered P2Y12 receptor antagonist, which has been approved for adult patients undergoing percutaneous coronary intervention and, due to its unique pharmacokinetics, it allows effective and controllable peri-procedural platelet inhibition. We report the case of a 6-year-old child with anomalous origin of right coronary artery from aortic left coronary sinus, who underwent elective surgical replacement of stenotic and calcified conduit between the right ventricle and the main pulmonary artery. The surgery was complicated by acute myocardial infarction secondary to coronary extrinsic compression. The patient was successfully treated with urgent percutaneous coronary intervention (simultaneous V-stenting) and cangrelor infusion, subsequently switched to clopidogrel therapy.